Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 19;11(12):3501–3509. doi: 10.1111/1759-7714.13689

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The best response of enrolled patients received immunotherapy. (a) The overall response rate (ORR) was not significant different between immunotherapy as single regimens and combination regimens () PR, () SD, and () PD. (b) The best response rate of all enrolled patients with immunotherapy is illustrated () combination therapy, and () monotherapy. (c) The ORR was not statistically different among three different combination immunotherapy regimens. (d) The best response rate of all enrolled patients with combination immunotherapy is illustrated () ICIs plus antiangiogenic, () ICIs plus chemotherapy, and () ICIs plus chemotherapy and antiangiogenic drugs.

Inline graphic — The best response of enrolled patients received immunotherapy. (a) The overall response rate (ORR) was not significant different between immunotherapy as single regimens and combination regimens () PR, () SD, and () PD. (b) The best response rate of all enrolled patients with immunotherapy is illustrated () combination therapy, and () monotherapy. (c) The ORR was not statistically different among three different combination immunotherapy regimens. (d) The best response rate of all enrolled patients with combination immunotherapy is illustrated () ICIs plus antiangiogenic, () ICIs plus chemotherapy, and () ICIs plus chemotherapy and antiangiogenic drugs.